National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.

Rapid Review

Commenced Completed Outcome
14/07/2016 18/08/2016 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
03/01/2017  01/06/2017 Reimbursement Recommended

Summary

The NCPE recommends reimbursement of Migalastat (Galafold®) subject to the continuing availability of a patient access scheme.